CClinicalTrials.gg
CompletedNCT03547843ADHDUpdated Jan 27, 2022

The Effects of Peer Co-led Educational Group Intervention for Adults With Attention-Deficit Hyperactivity Disorder

An interventional study of Group-based education and Waiting list in Attention Deficit Disorder With Hyperactivity, sponsored by Norwegian University of Science and Technology. Completed at 1 site in Norway. Open to participants aged 18 Years to 67 Years. Per ClinicalTrials.gov, last updated 2022-01-27.

Sponsored by Norwegian University of Science and Technology · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
18 Years to 67 Years
Sex
All
01

Study summary

Peer co-led education describes educators who are expert patients, user representatives or former patients, participating and teaching in educational interventions in cooperation with health care professionals. Peer co-led education is included in the Norwegian national guidelines for treatment of mental disorders, but despite some promising results for the treatment of other conditions, still little is known about the efficacy of peer co-led educational group interventions interventions for adults with attention deficit and hyperactivity disorder (ADHD).

This pilot trial will evaluate patient satisfaction with and preliminary efficacy of a 2-session peer co-led educational group program designed to address specific challenges faced by adults diagnosed with ADHD at an outpatient clinics in mid-Norway.

02

Conditions studied

  • Attention Deficit Disorder With Hyperactivity

Keywords

  • Behavior therapy
  • Peer groups
  • Patient satisfaction
  • Feasibility studies
03

In context

Hyperkinesis

729 studies on the registry are indexed under Hyperkinesis; 25 are open to participants now.

This study's enrollment of 56 is below the median of 80 across 583 interventional studies indexed under Hyperkinesis.

Browse Hyperkinesis studies →

Lead sponsor

Norwegian University of Science and Technology is the lead sponsor of 487 studies on the registry; 52 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 67 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Confirmed ADHD-diagnosis
  • speaking a Scandinavian language

Exclusion criteria

Exclusion Criteria:

  • Unable to give informed consent
  • Psychosis
  • Severe learning difficulties
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
56 participants (actual)

Study arms

  • Experimental
    Educational intervention

    Patients randomized to the intervention group will start with a group-based educational program immediately after the randomization.

    Behavioral: Group-based education · Other: Standard treatment

  • Active comparator
    Waiting list

    Participants randomized to the waiting list control group receive no educational intervention for the duration of the 10 weeks. During this period participants can receive standard treatment, consisting of diagnostic treatment with medication.

    Behavioral: Waiting list · Other: Standard treatment

Interventions

  • BehavioralGroup-based education

    The group-based educational program consists of two sessions that run over two consecutive weeks. Each session consists of a lecture from a recruited expert on the topic of the session and by expert patients with a following discussion of the topic facilitated by the course leader.

    Also known as: Patient education

  • BehavioralWaiting list

    No educational intervention for the duration of the 10 weeks. During this period participants can receive standard treatment.

  • OtherStandard treatment

    Diagnostic treatment with medication. In addition, some patients receive cognitive behavioral therapy (not systematically given to every patient). If needed, patients are also offered assistance with regard to economy, housing, education, and work as well as contact with family and network.

    Also known as: Treatment as usual

06

What researchers measure

Primary outcomes

  1. Change in client Satisfaction

    Client satisfaction will be measured with Client Satisfaction Questionnaire, short form (Attkisson \& Zwick, 1982). The scale consists of 8 items scored on a Likert scale from 1 (low satisfaction) to 4 (high satisfaction). Total scores range from 8 to 32, with higher scores indicating greater satisfaction.

    Time frame: from baseline to 2-weeks follow-up

  2. change in patient activation

    Patient activation will be measured with the Norwegian version of the Patient Activation Measure Mental Health (PAM-MH) (Green et al 2010))

    Time frame: from baseline to 10-weeks follow-up

Secondary outcomes

  1. change in general self-efficacy

    General Self-Efficacy Scale, 6-item scale ranging from 1 ('not at all true') to 4 ('exactly true'). Total scores range from 6 to 24, with higher scores indicating greater self-efficacy. (Romppel et al 2013)

    Time frame: from baseline to 10 weeks follow-up

  2. change in ADHD-related symptoms

    Hopkin's Symptom Checklist (SCL), 9-items scale with high scores on SCL-9 indicating ADHD-related symptom burden (Eich et al 2011)

    Time frame: from baseline to 10 weeks follow-up

  3. change in ADHD-related symptoms

    Norwegian version of the WHO Adult ADHD Self-report scale, ASRS Short Form (Kessler et al 2005)

    Time frame: from baseline to 10 weeks follow-up

  4. change in Quality of Life

    Adult Attention Deficit/Hyperactivity Disorder Quality of Life Scale, AAQoL short Form (Brod et al 2006)

    Time frame: from baseline to 10 weeks follow-up

Other outcomes

  1. Use of health services and work participation

    Self-reported work participation and received services: 3 questions about both work status and received treatment

    Time frame: through study completion, an average of 24 weeks

07

Study locations

1 site
  • Tiller DPS
    Trondheim, 7055, Norway
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 27, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03547843
Lead sponsor
Norwegian University of Science and Technology
Collaborators
St. Olavs Hospital
Responsible party
Sponsor
First posted
Jun 6, 2018
Start date
May 31, 2018
Primary completion
Mar 15, 2020
Completion
Mar 15, 2020
Last update
Jan 27, 2022

Study contacts

Anne-Lise Løvaas, md phd
study director · St. Olavs Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion